Lilly, Care Access Take COVID Trial Directly To Patients
By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical
Eli Lilly and Company and Care Access Research have forged a unique partnership to develop and manage a first-of-its kind decentralized, mobile trial to safeguard the health of patients in nursing homes. Lilly and Care Access will take the trial directly to patients. Lilly has worked with Care Access Research, a decentralized research organization (DRO) that operates as one connected team of physicians and nurses, for several years.
“Lilly has spent years figuring out ways to be more innovative with our clinical trials,” says Nicole Sheetz, clinical systems director at Lilly. “We are passionate about doing more for our patient community and the effort with Care Access Research is an example of that. We are working hard to try and move away from slow and cumbersome trials that are centered in large hospitals. We have implemented a relatively aggressive yet pragmatic seven-year strategy to implement decentralized trials. Our focus is to bring the trial to the patient and meeting them where they are, regardless of their background and location.”